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ABSTRACT 
Objective: Flare in Systemic Lupus Erythematosus (SLE) is an exacerbation of SLE clinical features that were earlier quiescent. The disease activity 
changes from inactive to active with an increase of several immunological profiles; the rise of immune activity induces a metabolic shift in SLE 
patients. The previous study aimed to investigate the long and very long fatty acid fractions (LCFA and VLCFA) in the active and inactive statuses of 
SLE patients and showed there were dynamic changes in fatty acid fractions in SLE patients, compared to healthy subjects. The aim of this 
preliminary study is to investigate LCFA and VLCFA in the active and inactive condition of SLE patients.  
Methods: Four serum samples of active and inactive statuses from the same SLE patients were used in this study. Serum LCFA and VLCFA fractions 
were analyzed by a 7890 Gas Chromatography (GC) System 5977 Mass Selective Detector (MSD).  
Results: All of the LCFA and VLCFA fractions were increased in the active condition, compared to SLE patients in inactive, although they were 
statistically not different (p>0.05). The total fatty acid fraction was 38% higher in active condition compare to inactive. The prominent increase of 
fatty acid fractions was alpha-linolenic acid (inactive vs. active: 23.25±17.97 vs 48.25±38.58 μmol/l), oleic acid (1300±190.4 vs 1774±866.3 μmol/l) 
and myristic acid (31.25±12.76 vs 59.25±40.4 μmol/l). 
Conclusion: The serum of LCFA and VLCFA fractions in SLE patients tend to increase in active conditions. 
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Incidences of Systemic Lupus Erythematosus (SLE) have increased 
around the world, with race, gender, and ethnicity affecting the 
incidences. A review by Stojan and Petri showed Asians had a higher 
incidence and prevalence of SLE compared to Caucasians, but lower 
than African Americans [1]. In Indonesia, the prevalence of this 
disease is 0.5% of the total population with a tendency toward an 
increased number of incidences every year, and women 15–44 y of 
age are more likely to be affected [2]. From other previous study, 
which was conducted from 2008 to 2017, showed 95.6% of 813 SLE 
patients were female, and there was an 8.1% mortality rate [3]. 
SLE is known as the disease with multi-organ involvement and is 
characterized by a relapse-remission pattern or flare pattern. Flare 
in SLE is an exacerbation of SLE clinical features that were earlier 
quiescent. This condition is indicated active disease by an increase 
of several immunological profiles; inflammation is marked by an 
intensifying number of cytokines, chemokines and reactive oxygen 
species (ROS) that act as immunological activities of this disease [3, 
4]. These activities induce metabolic shifts in SLE patients, including 
free fatty acids (FFAs) levels.  
Several previous studies proposed a correlation between FFA 
metabolism and SLE [5, 6]. There is a dynamic change of fatty acid 
fractions in SLE patients compared to healthy subjects. LCFA and 
VLCFA, including palmitoleic, myristic and eicosenoic acids, 
significantly increase in SLE patients. Conversely, the level of 
linoleic, stearic, caproic, eicosanoic and arachidonic acids 
significantly decrease in SLE patients [7]. Based on saturation, fatty 
acid is categorized as unsaturated fatty acids (oleic, palmitoleic, 
eicosenoic, linoleic, stearic and arachidonic acids) and saturated 
fatty acids (myristic, caproic and eicosanoic acids) [8]. The plasma of 
patients with SLE contains low concentrations of polyunsaturated 
fatty acids and high levels of saturated fatty acids [9].  
There was an alteration of the lipid profile between active and 
inactive of patients with SLE. The ratio of low-density lipoprotein 
cholesterol to high-density lipoprotein cholesterol significantly 
increased in active conditions suggesting a high risk of 
atherosclerosis evidence in SLE patients [10]. Further investigation 
is necessary to analyze fatty acid fractionation between active and 
inactive conditions in SLE patients. 
MATERIALS AND METHODS 
Subjects 
This was a cross-sectional study. The participants were four patients 
who were referred to the rheumatology clinic, our hospital, in 2018. 
Participants were selected because they had periodically 
experienced inactive and active disease activity. Patients fulfilled at 
least four classification criteria as defined in 1997 by the American 
College of Rheumatology [11]. Disease activity was assessed with the 
SLEDAI-2K, for which ≥ 4 is defined as an active disease and<4 as 
inactive [12]. The patient’s histories were reviewed and 
demographic and SLE-related data were collected. All patients 
provided fully informed consent to participate. This study was 
approved by the ethical committee of our university. 
Fatty acid quantification 
Fasting venous blood samples were collected in ethylene diamine-
tetra-acetic acid (EDTA) or sera tubes and immediately centrifuged 
at 4 °C, 1500 rpm for 15 min. The samples were then divided into 
aliquots and stored at-80 °C until further examination. Four serum 
samples of active and inactive disease activity from the same SLE 
patients were used in this study. Serum LCFA and VLCFA were 
analyzed in the xxx Laboratory by a 7890 GC System 5977 MSD. 
One hundred ul serum was prepared by adding 150 ul methanol 
(Merck, Germany); then 300 ul diluent, which contains chloroform 
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(Merck, Germany) and non-decanoate, C19:0 (Supelco) as the 
internal standard, was added. The serum mixture was then 
centrifuged at 2500 g for five minutes and the layer of chloroform, 
which contains analyte supernatant, was transferred to different 
tubes. The chloroform phase evaporated with nitrogen to dryness. 
The fatty acid resolved with n-hexane (Merck, Germany), which 
contains Tetramethyl Ammonium Hydroxide (TMAH) in methanol 
(Sigma), and incubated two hours for esterification, after which it 
was transferred to GC vials. 
Fatty acid calibration curve was prepared by diluting the stock of 
FAME Mix, C4-C24 (Cat. 18919-1AMP, Lot. LC16765V, Supelco, 
Bellefonte, PA, USA) with n-Hexane (Merck, Germany) and 1.5 N 
Hydrochloric Acid (Merck, Germany). Stock of FAME Mix standard 
consists of Myristic (C14:0), Palmitic (C16:0), Palmitoleic (C16:1 w7), 
Stearic (C18:0), Oleic (C18:1 w9), Linoleic (C18:2 w6), y-Linolenic 
(C18:3 w6), a-Linolenic (C18:3 w3), AA (C20:4 w6), DGLA (C20:3 w6), 
EPA (C20:5 w3) and DHA (C22:6 w3). The stock of the FAME standard 
was serial-diluted to nine levels of calibration and transferred to GC 
vials. The concentration for each fatty acid varied according to the 
certificate of analysis. Nonadecanoat, C19:0 (Supelco) was used as an 
internal standard and added to every level of the calibration standard. 
Standard and sample were injected into the 7890 GC System 5977 
MSD (Agilent Technologies, USA) with Electron Impact (EI) source. 
Fatty acids were separated through a HP88 column (30 m x 0.25 mm 
x 0.25 um film thickness). GC oven temperature was set to increase 
from 50 °C to 180 °C with a 7.07 °C increase-rate-per-minute and 
180 °C to 230 °C with a 7.07 °C increase-rate-per-minute. MSD was 
set in SIM mode. Fatty acid concentration was quantified by 
constructing 9 levels of the calibration curve with the internal 
standard calculation [13-15]. 
Statistical analysis 
Statistical analyses were performed using the GraphPad statistical 
package. Variables were summarized using the mean±SD. Normal 
distribution was assessed with the Kolmogorov-Smirnov test. The p-
value was calculated using the paired t-test for normal distribution 
and the Wilcoxon test for skewed data. Two-tailed p-values<0.05 
were considered statistically significant. 
RESULTS 
The mean current age of the patients with SLE was 33±6.98 y. The 
mean age at the first visit was 28.75±7.14 y, while the mean age at 
diagnosis was 20.25±5.19 y. Two patients were overweight, and no 
patients were obese; musculoskeletal and renal abnormalities were 
found in most of the patients. This study also showed a trend of 
higher SBP and DBP in active condition, even though it was 
statistically insignificant (p>0.05). 
  
Table 1: Characteristics of the patients in an inactive and active state of our hospital 
 Patient SLE (n=4) Inactive  Active  p-value 
Current age, yo, mean±SD 33±6.98    
Age when diagnosed, yo, mean±SD 20.25±5.19    
Age when the first visit, yo, mean±SD 28.75±7.14    
Disease Duration, year, mean±SD 12.75±6.13    
BMI, kg/m2, n (%)     
Normal (18.5–24.9) 2 (50%)    
Overweight (25.0–29.9) 2 (50%)    
Clinical Symptomatology, n (%)     
Mucocutaneous 1 (25)    
Musculoskeletal 3 (75)    
Renal 3 (75)    
Hematology 1 (25)    
Ocular 1 (25)    
SBP, mm/Hg, mean±SD  125±16.51 142.7±23.86 0.29 
DBP, mm/Hg, mean±SD  77.5±10.6 89.33±16.77 0.34 
ESR, mm/hour, mean±SD   48.75±26.4 43±16.27 0.77 
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; yo= years 
old. N=54 patients. The p-value was calculated using the Paired t-test. This test for comparing the values of the patients in active and inactive conditions. 
 
Table 2: Generally, LCFA and VLCFA increased in SLE patient in the active state 
No Free fatty acid Patient SLE state p-value 
Inactive  Active  
1 Alpha-Linolenic Acid (ALA) (µmol/l) 23.5±17.97 48.25±38.58 0.41 
2 Eicosapentaenoic Acid (EPA)(µmol/l) 17.25±12.58 27.75±7.63 0.63 
3 Docosahexaenoic Acid (DHA)(µmol/l) 158±106.10 234.25±83.51 0.44 
4 Omega 3(µmol/l) 199±132.87 300.75±126.82 0.46 
5 Linoleic Acid (µmol/l) 1680±569.11 2294.5±823.72 0.63 
6 Gamma-Linoleic Acid (GLA)(µmol/l) 20.25±12.01 27.25±15.20 0.61 
7 Dihomo-gamma-linoleic Acid (DGLA)(µmol/l) 74±50.99 92±12.19 0.58 
8 Arachidonic Acid (AA)(µmol/l) 328.75±217.19 363±31.96 0.75 
9 Omega 6 (µmol/l) 2103.75±812.08 2777±842.54 0.47 
10 Oleic Acid (µmol/l) 1300±190.38 1773.75±866.35 0.4 
11 Myristic Acid (µmol/l) 31.25±12.76 59.25±40.41 0.27 
12 Palmitic Acid (µmol/l) 1355.25±317.53 1658.5±465.04 0.48 
13 Stearic Acid (µmol/l) 420.5±32.07 475.25±120.75 0.47 
14 Saturated (µmol/l) 1806.75±351.51 2193.25±617.39 0 
15 Palmitoleic Acid (µmol/l) 345.5±80.59 477.25±239.17 0.43 
16 Oleic Acid (µmol/l) 1300±190.38 1773.75±866.35 0.4 
17 Monounsaturated (µmol/l) 1645.75±247.23 2251.25±1100.46 0.4 
18 Polyunsaturated (µmol/l) 2302.75±942.75 3087.75±929.09 0.46 
19 Total Fatty Acid (µmol/l) 5755.25±1477.52 7531.75±2622.24 0.44 
20 Omega 6/Omega 3 20.975±22.25 9.5±3.46 0.63 
21 AA/EPA 21.75±6.70 13.5±3.70 0.14 
22 Omega 3 Index 3.25±2.22 4.25±1.26 0.42 
Data presented as mean±SD, n=4. The p-value was calculated using the paired t-test for normal distribution and Wilcoxon test for skewed data. 
These tests for comparing values of the patients in an active and inactive condition. 
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Table 2 shows an increase in LCFA and VLCFA in the active pattern 
of SLE patients in general, although it was not different statistically 
(p>0.05). The total fatty acid fraction was 38% higher in an active 
condition, compared to inactive.  
The prominent increases of fatty acid fractions were alpha-linolenic 
acid (inactive vs active: 23.25±17.97 vs 48.25±38.58 μmol/l), oleic 
acid (1300±190.4 vs 1774±866.3 μmol/l) and myristic acid 
(31.25±12.76 vs 59.25±40.4 μmol/l). Conversely, omega 6 and 
Omega 3 and AA/EPA index decreased in the active state 
(21.75±6.70 vs 13.5±3.70 and 3.25±2.22 vs 4.25±1.26, respectively). 
DISCUSSION 
SLE is an autoimmune disease that more often affects women of 
productive age [2]; this was in line with our results. We also showed 
renal abnormalities found in most of the patients. Renal abnormality 
is often found in SLE patients [7, 10]; this was also evident in the 
previous study, wherein they determined that 41.9% of the total 813 
SLE patients suffered renal abnormalities [3].  
In this current study, there was an increasing trend of LCFA and 
VLCFA in the active pattern of SLE patients in general. A higher 
level of total fatty acid was also found in this study. FFA was 
released from adipose tissue as a result of lipolysis; an increase 
of FFA can also be found in fasted [16, 17], in obesity that is the 
result of an increase of adipose tissue [18] or triggered by 
inflammation [19]. The concentration of FFA is higher in SLE 
patients compared to healthy subjects; this elevation is 
correlated with metabolic syndrome and insulin resistance, but 
not inflammation response [20]. Our study showed a further 
increase in total fatty acid, suggesting inflammation in the active 
condition triggers lipolysis. This condition can further increase 
the risk of metabolic syndrome and cardiovascular disease. 
The prominent increases in fatty acid fractions were alpha-linolenic 
acid, oleic acid and myristic acid. Alpha-linolenic acid is a member of 
the omega-3 polyunsaturated fatty acid family and functions as an 
anti-inflammatory agent, neuroprotectant and antidepressant [21]. 
Oleic acid is a monounsaturated omega-9 fatty acid that can 
modulate inflammation responses [22]. The increase of both alpha-
linolenic acid and oleic acid might be a response to inflammation in 
active conditions. Myristic acid is a saturated LCFA with a 14-carbon 
backbone, which has a role as a lipid anchor in bio-membranes [23]. 
Increasing myristic acid was positively correlated to higher 
cholesterol and triglyceride level in humans and increases the risk of 
coronary atherosclerosis [24]. A study by Posadas-Romero et al. 
showed high levels of saturated fatty acids in SLE patients, which is 
related to inflammatory and autoimmunity processes in the SLE 
disease [9]. We found a prominent increase in myristic acid in active 
condition of SLE patients; this condition could contribute to the risk 
of coronary atherosclerosis in these patients. 
CONCLUSION 
The serum of LCFA and VLCFA in SLE patients are tending to 
increase in flare condition. 
ACKNOWLEDGEMENT 
We thank Prodia Laboratory–Indonesia for doing the FFA measurement. 
We also thank Neni Anggraeni and Vanessa Ayu Sumirat for excellent 
technical help. 
This article was presented in the 4th International Conference and 
Exhibition on the Indonesian Medical Education and Research Institute 
(ICE on IMERI 2019), Faculty of Medicine, Universitas Indonesia. We 
thank the 4th ICE on IMERI committee, who had supported the peer 
review and manuscript preparation before submitting to the journal. 
FUNDING 
This work was supported by the PUPT Research Grant from the Ministry 
of Research, Technology and Higher Education of the Republic of 
Indonesia (Kemenristek Dikti). 
AUTHORS CONTRIBUTIONS 
All authors have contributed equally. 
CONFLICT OF INTERESTS 
All authors have none to declare. 
REFERENCES 
1. Stojan G, Petri M. Epidemiology of systemic lupus 
erythematosus: an update. Curr Opin Rheumatol 2018;30:144–
50. 
2. Pusat Data dan Informasi Kementrian Kesehatan Republik 
Indonesia. Situasi Lupus di Indonesia. Jakarta: Pusdatin 
Kemenkes RI; 2017. 
3. Hamijoyo L, Candrianita S, Rahmadi AR, Dewi S, Darmawan G, 
Suryajaya BS, et al. The clinical characteristics of systemic 
lupus erythematosus patients in Indonesia: a cohort registry 
from an Indonesia-based tertiary referral hospital. Lupus 
2019;28:1604–9. 
4. Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, 
James JA. Proinflammatory adaptive cytokine and shed tumor 
necrosis factor receptor levels are elevated preceding systemic 
lupus erythematosus disease flare. Arthritis Rheumatol 
2014;66:1888–99. 
5. Ferreira HB, Pereira AM, Melo T, Paiva A, Domingues MR. 
Lipidomics in autoimmune diseases with main focus on 
systemic lupus erythematosus. J Pharm Biomed Anal 
2019;174:386–95. 
6. Yan B, Huang J, Zhang C, Hu X, Gao M, Shi A, et al. Serum 
metabolomic profiling in patients with systemic lupus 
erythematosus by GC/MS. Mod Rheumatol 2016;26:914–22. 
7. Shin TH, Kim HA, Jung JY, Baek WY, Lee HS, Park HJ, et al. 
Analysis of the free fatty acid metabolome in the plasma of 
patients with systemic lupus erythematosus and fever. 
Metabolomics 2017;14:14. 
8. Rodwell VW, Bender DA, Botham KM, Kennelly PJ, Weil PA. 
Harper's Illustrated Biochemistry. 31st ed. New York: McGraw-
Hill Education; 2018. 
9. Posadas Romero C, Torres Tamayo M, Zamora Gonzalez J, 
Aguilar Herrera BE, Posadas Sanchez R, Cardoso Saldana G, et 
al. High insulin levels and increased low-density lipoprotein 
oxidizability in pediatric patients with systemic lupus 
erythematosus. Arthritis Rheum 2004;50:160–5. 
10. Urquizu Padilla M, Balada E, Chacon P, Perez EH, Vilardell 
Tarres M, Ordi Ros J. Changes in lipid profile between flare and 
remission of patients with systemic lupus erythematosus: a 
prospective study. J Rheumatol 2009;36:1639–45. 
11. Hochberg MC. Updating the American College of rheumatology 
revised criteria for the classification of systemic lupus 
erythematosus. Arthritis Rheum 1997;40:1725. 
12. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus 
erythematosus disease activity index 2000. J Rheumatol 
2002;29:288–91. 
13. Ren J, Mozurkewich EL, Sen A, Vahratian AM, Ferreri TG, Morse 
AN, et al. Total serum fatty acid analysis by GC-MS: assay 
validation and serum sample stability. Curr Pharm Anal 
2013;9:331–9. 
14. Lagerstedt SA, Hinrichs DR, Batt SM, Magera MJ, Rinaldo P, 
McConnell JP. Quantitative determination of plasma c8-c26 
total fatty acids for the biochemical diagnosis of nutritional and 
metabolic disorders. Mol Genet Metab 2001;73:38–45. 
15. Abdelmagid SA, Clarke SE, Nielsen DE, Badawi A, El-Sohemy A, 
Mutch DM, et al. Comprehensive profiling of plasma fatty acid 
concentrations in young healthy Canadian adults. PLoS One 
2015;10:e0116195. 
16. Syamsunarno MR, Iso T, Hanaoka H, Yamaguchi A, Obokata M, 
Koitabashi N, et al. A critical role of fatty acid-binding protein 4 
and 5 (FABP4/5) in the systemic response to fasting. PLoS One 
2013;8:e79386. 
17. Putri M, Syamsunarno MR, Iso T, Yamaguchi A, Hanaoka H, 
Sunaga H, et al. CD36 is indispensable for thermogenesis under 
conditions of fasting and cold stress. Biochem Biophys Res 
Commun 2015;457:520–5. 
18. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: 
integrating signaling pathways and substrate flux. J Clin Invest 
2016;126:12–22. 
Syamsunarno et al. 
Int J App Pharm, Vol 12, Special Issue 3, 2020, 83-86 
4th International Conference and Exhibition on Indonesian Medical Education and Research Institute 2019              | 86 
19. Fritsche KL. The science of fatty acids and inflammation. Adv 
Nutr 2015;6:293S–301S. 
20. Ormseth MJ, Swift LL, Fazio S, Linton MF, Raggi P, Solus JF, et al. 
Free fatty acids are associated with metabolic syndrome and 
insulin resistance but not inflammation in systemic lupus 
erythematosus. Lupus 2013;22:26–33. 
21. Blondeau N, Lipsky RH, Bourourou M, Duncan MW, Gorelick 
PB, Marini AM. Alpha-linolenic acid: an omega-3 fatty acid with 
neuroprotective properties–ready for use in the stroke clinic? 
Biomed Res Int 2015. DOI:10.1155/2015/519830. 
22. Sales Campos H, Souza PR, Peghini BC, da Silva JS, Cardoso 
CR. An overview of the modulatory effects of oleic acid in 
health and disease. Mini Rev Med Chem 2013;13:201–10. 
23. Nelson DL, Lehninger AL, Cox MM. Lehninger principles of 
biochemistry. 5th ed. New York: WH Freeman; 2008. 
24. German JB, Dillard CJ. Saturated fats: a perspective from 
lactation and milk composition. Lipids 2010;45:915–23. 
 
